Search the Newsreel

Kaplan Fox Encourages Investors of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) to Contact the Firm to Learn About Their Legal Rights

Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against PROCEPT BioRobotics Corporation (NASDAQ: PRCT) on behalf of investors who purchased common stock between February 28, 2024, and February 25, 2026. The lawsuit alleges that PROCEPT artificially inflated its reported U.S. handpiece …

Is Aptiv Stock a Buy Now as Low Valuation Meets Rising Execution Risk?

Aptiv PLC (APTV) shows a low valuation and improved operating execution, with second-quarter margins rising and non-automotive revenues growing. However, this discount is tied to lowered earnings estimates, reduced full-year guidance, and weakened first-half free cash flow. While its valuation appears attractive on key …

APTV Cuts 2026 Outlook After Q2 Beat as China and Launch Delays Weigh

Aptiv PLC APTV cleared second-quarter earnings expectations, but the quarter's more consequential signal came from a reduced 2026 outlook. The change shifts attention from margin execution toward demand, customer mix and program timing. The question for investors is how much of the second-half pressure …

Raymond James Maintains Septerna(SEPN.US) With Buy Rating, Cuts Target Price to $49

Raymond James has reiterated its Buy rating for Septerna (SEPN.US) but has adjusted its price target downwards to $49. This indicates a continued positive outlook on the company's prospects despite a revision in the expected share price. Investors may see this as a signal …

Septerna (NASDAQ:SEPN) Stock Price Up 9% Following Earnings Beat

Septerna (NASDAQ:SEPN) shares rose 9% after reporting better-than-expected quarterly earnings, with an EPS of negative $0.29 against estimates of negative $0.43, and revenue of $26.75 million exceeding the $19.22 million consensus. Despite broad analyst positivity and a "Moderate Buy" consensus rating, the company remains …

AdaptHealth at Canaccord Genuity’s 46th annual growth conference: refocus deepens

AdaptHealth discussed its business transition at Canaccord Genuity's 46th Annual Growth Conference, focusing on organic growth, debt reduction, and core home medical equipment lines after divesting its diabetes business. The company highlighted strong sleep care demand and 16% Q2 2024 revenue growth, despite facing …

AdaptHealth (NASDAQ:AHCO) Trading Up 10.5% on Insider Buying Activity

AdaptHealth (NASDAQ:AHCO) saw its stock price increase by 10.5% due to significant insider buying activity, specifically by Director Kenneth A. Samet, who increased his holdings by 93.7% with a purchase worth nearly $150,000. Analyst sentiment is mixed but leans positive, with seven analysts rating …

Lost Money on PROCEPT BioRobotics Corporation (PRCT)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm

The Gross Law Firm has issued a notice to shareholders of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) to join a class action lawsuit. The suit alleges that PROCEPT BioRobotics Corporation made false or misleading statements regarding an undisclosed discount program that inflated sales and revenue, …

AdaptHealth Sells Diabetes Unit to Sharpen Focus on Sleep, Respiratory Growth

Key Points Interested in AdaptHealth Corp.? Here are five stocks we like better. AdaptHealth is selling its roughly $600 million diabetes business to Cardinal Health and exiting certain e-commerce and drop-ship operations to simplify the company and focus on sleep, respiratory and home medical …

MetaOptics Ltd achieves 79% of FY2025 full-year revenue in 1H 2026, on track to fulfil purchase orders of key metalens production equipment in 2H 2026

Genscript Highlights Legend Biotech’s Q2 Results and Cautions Investors

Stifel raises Septerna stock price target to $49 on SEP-479 outlook

Stifel has increased its price target for Septerna Inc. (NASDAQ:SEPN) to $49 from $43, maintaining a Buy rating due to an improved outlook for SEP-479, a hypoparathyroidism drug. The firm raised the drug's probability of success to 50% from 33% based on positive preclinical …

Optimum Communications (OPTU): Evaluating a Tender Offer Arbitrage

Investment management company Curreen Capital released its second-quarter 2026 Investor letter. A copy of the letter can be downloaded here. In the second quarter, the fund returned 22.26% compared to 15.20% for the S&P 500 Index. The performance was driven by active special case …

MetaOptics surges on 1H revenue jump and strong metalens order backlog

MetaOptics H1 revenue grows by nearly six times; company on track to fill orders in H2

AIxCrypto Holdings' Shocking Year-Long Related-Party Deal Raises Red Flags

AIxCrypto Holdings has disclosed a year-long consulting agreement with Aibot US Operation Inc., a related party sharing common ownership with the company's controlling shareholders. This disclosure, made via an 8-K filing with the SEC, has raised governance concerns among investors due to the potential …

Guggenheim raises Septerna stock price target to $51 on pipeline progress

Guggenheim has increased its price target for Septerna Inc. (NASDAQ:SEPN) to $51 from $45, maintaining a Buy rating, due to pipeline progress and an increased probability of success for its drug candidate SEP-479. The company is also exploring new indications for SEP-631 and expects …

Transaksi Saham Guna Timur (TRUK) Kembali Dibuka, Bakal Lanjutkan Kenaikan?

PRCT Investor Announcement: PROCEPT BioRobotics Sued on behalf of Investors to Recover Losses after Artificially Inflated Revenue Leads to 18% Stock Drop

OPTEX SYSTEMS ($OPXS) Releases Q3 2026 Earnings

OPTEX SYSTEMS ($OPXS) released its Q3 2026 earnings, reporting $0.18 per share, missing estimates by $0.05, and revenue of $9.73 million, missing estimates by $2.816 million. Following the announcement, the stock price decreased by 1.82%. The article also details recent insider trading activity, institutional …

Corcept Therapeutics Incorporat (CORT) Stock Forecasts

Argus has raised its target price for Corcept Therapeutics Inc (CORT) to $115.00, noting the company's focus on developing medications for severe metabolic, oncologic, and neuropsychiatric disorders. The current price for CORT is $111.86. The report emphasizes the company's commercial-stage pharmaceutical operations.

Adaptive Biotechnologies Corp (ADPT) Stock Analysis: Navigating the Growth Path with a 21.5% Revenue Surge

Adaptive Biotechnologies Corp (ADPT) is a commercial-stage company leveraging its immune medicine platform for diagnostics and treatment, showing a 21.5% revenue growth. Despite current losses and a negative Forward P/E, the company has a strong market capitalization of $4.05 billion and positive analyst sentiment …

Neo-Concept International (NCI) CFO Peter Pang files initial Form 3 ownership

Neo-Concept International Group Holdings Ltd's CFO, Peter Chun Ming Pang, has filed an initial Statement of Beneficial Ownership (Form 3) with the SEC. This filing indicates his position as an officer but does not report any actual holdings or transactions at this time. The …

Why Did Adaptive Biotechnologies (ADPT) Move After Its Latest Update?

99,902 Shares in AptarGroup, Inc. $ATR Acquired by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. has acquired 99,902 shares of AptarGroup, Inc. (NYSE:ATR) worth approximately $12.5 million, marking a new stake in the company. AptarGroup also reported strong quarterly earnings, exceeding expectations with $1.42 EPS and $1.03 billion in revenue, and declared a quarterly dividend …

Pacer Advisors Inc. Reduces Stock Holdings in Aptiv PLC $APTV

Pacer Advisors Inc. significantly reduced its stake in Aptiv PLC (APTV) by 99.5% in the first quarter, selling over 2.2 million shares and retaining only 11,515 shares. Despite this, institutional investors still hold a substantial 94.21% of Aptiv's stock. The article also details other …

Adapthealth director Kenneth Samet buys $149,930 in shares

AdaptHealth Corp. director Kenneth Samet recently purchased 23,500 shares of company stock for $149,930, bringing his total holdings to 48,569 shares. This insider purchase occurs while AHCO stock is trading near its 52-week low, with InvestingPro analysis suggesting it is undervalued. The company recently …

Adaptive Biotechnologies stock hits 52-week high at 25.04 USD By Investing.com

Adaptive Biotechnologies (ADPT) stock has reached a 52-week high of $25.04, reflecting a 104% increase over the past year and underscoring strong performance in the biotechnology sector. The company's market capitalization is now $3.95 billion, with 50% revenue growth, indicating strong investor confidence. This …

AirSculpt Technologies (AIRS) Reaffirmed Guidance, Is The Sell Off Hiding Value?

Neptune Insurance Holdings Inc. $NP Stock Holdings Lifted by Sei Investments Co.

Treace Medical Concepts, Inc. (NASDAQ:TMCI) Given Consensus Rating of "Reduce" by Analysts

Analysts have issued a consensus "Reduce" rating for Treace Medical Concepts, Inc. (NASDAQ:TMCI), with an average 12-month price target of $5.17, despite the company beating recent quarterly revenue and EPS estimates. The stock opened at $4.67, and significant insider and institutional ownership is noted. …

Vault Minerals (ASX:VAU) Gains 122% in One Year, Gold Output and Merger Plans Reshape Growth

First Trust Advisors LP Reduces Holdings in Option Care Health, Inc. $OPCH

First Trust Advisors LP significantly reduced its stake in Option Care Health, Inc. (NASDAQ:OPCH) by 53% in the first quarter, selling 43,153 shares and retaining 38,226 shares valued at approximately $1.03 million. Despite this, institutional investors collectively hold a substantial 98.05% of the company's …

First Trust Advisors LP Decreases Stock Position in COPT Defense Properties $CDP

First Trust Advisors LP significantly reduced its stake in COPT Defense Properties (NYSE:CDP) by 73.4% in the first quarter, selling over 75,000 shares. Despite this, other institutional investors have increased their holdings, and analysts maintain a "Moderate Buy" rating with an average price target …

Dimensional Fund Advisors LP Sells 121,412 Shares of Sarepta Therapeutics, Inc. $SRPT

Dimensional Fund Advisors LP significantly reduced its stake in Sarepta Therapeutics, Inc. by selling 121,412 shares, leaving them with 336,736 shares valued at $7.3 million. Despite institutional investors owning a large portion of the company and some increasing their positions, analyst sentiment is mixed, …

Sarepta Therapeutics, Inc. (SRPT) Investor Outlook: Analyzing The 31.63% Potential Upside

Sarepta Therapeutics (SRPT) is a biotechnology firm focusing on RNA-targeted therapeutics and gene therapies for rare diseases like Duchenne muscular dystrophy, with a market capitalization of $1.77 billion. Despite a revenue decline of 34.30% and negative EPS, analysts project a 31.63% potential upside, driven …